Nicotinamide adenine dinucleotide phosphate oxidase–mediated redox signaling and vascular remodeling by 16α-hydroxyestrone in human pulmonary artery cells by Hood, Katie Y. et al.
1The prevalence of pulmonary arterial hypertension (PAH) is greater in women than in men. Exact reasons for this 
sex-related difference remain unclear although increasing 
evidence suggests that metabolites of 17β-estradiol (estro-
gen) may play a role.1–3 Despite the female predominance 
and pathological implications of estrogens in human PAH, 
some experimental models have shown that exogenous 
estrogen is protective.4 The apparent contradictions may 
be explained by differential effects of estrogen metabolites 
on pulmonary vascular function and right ventricular (RV) 
homeostasis.5,6
Estrogen is metabolized by cytochrome P450 (CYP) 
enzymes7,8 to both proproliferative and antiproliferative 
metabolites.9 CYP 1B1 (CYP1B1) is a P450 enzyme expressed 
in the lung, which catalyses the conversion of estrogens pre-
dominantly to 4-hydroxyestrogens but also to 2-hydroxy 
and 16-hydroxyestrogens,10 and has been implicated in idio-
pathic PAH1 and heritable PAH.3,11,12 16α-hydroxyestrone 
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(16αOHE1) is a biologically active metabolite with estrogenic 
activity. It is more potent than that of estrogen.13 16αOHE1 
stimulates cell proliferation and has been implicated in exper-
imental PAH,1 as well as having genotoxic effects in other 
systems.14 Molecular processes underlying these effects are 
unclear, although reactive oxygen species (ROS) may be 
important because estrogen, through its estrogen receptor 
(ER), and estrogen metabolites have been shown to cause cell 
proliferation through redox-sensitive processes.15
Increased bioavailability of ROS (superoxide anion [∙O2−]) 
hydroxyl radical and hydrogen peroxide [H2O2]) leads to a 
shift in the balance between pro-oxidants and antioxidants and 
has been implicated in the development of various cardiovas-
cular diseases, including PAH.16–18 The nicotinamide adenine 
dinucleotide phosphate oxidase (Nox) family of enzymes is 
the primary source of ROS production in the vasculature, 
where increased expression of Nox isoforms 1 and 4 in the 
pulmonary vasculature has been demonstrated in experimen-
tal models of PAH.16–18
In support of the importance of Noxs in PAH, studies in 
rat models demonstrated that antioxidants, such as resvera-
trol analogs, improved pulmonary hypertension16 and that in 
mice, mitochondria-localized Nox4 activity is increased in the 
early phase of pulmonary hypertension.17 Moreover, in pul-
monary artery smooth muscle cells (PASMCs) isolated from 
monocrotaline-induced pulmonary hypertension, activation of 
Nox1, but not Nox4, was increased and Nox1-dependent sig-
naling pathways were upregulated.18 Counter-regulating pro-
oxidants in vascular cells are antioxidants; many of which are 
controlled by nuclear factor erythroid–related factor 2 (Nrf2), 
a key transcription factor that influences activation of antioxi-
dant genes, such as superoxide dismutase (SOD), catalase, 
and thioredoxin, which protect against oxidative damage.19 
Although oxidative stress may be important in the pathophysi-
ology of PAH, the relationship to estrogen and its metabolites 
and the potential significance in women remain unclear.
We hypothesized that 16αOHE1 stimulates Nox-induced 
ROS generation and proliferative responses in PASMCs and 
that in PAH, Nox dysregulation, and Nrf2 downregulation 
leads to aberrant mitogenic signaling and increased cell pro-
liferation, which are important in vascular remodeling in PAH. 
Because of the preponderance of PAH in women, we focused 
our study on PASMCs from well-characterized female patients. 
To investigate the pathophysiological significance of estrogen–
Nox–dependent processes in PAH, we studied female Nox1−/− 
and Nox4−/− mice with pulmonary hypertension.
Materials and Methods
A detailed Methods section is provided in the online-only Data 
Supplement.
Cell Culture
In vitro studies were performed using primary cultures of human 
PASMCs (hPASMCs) from small distal arteries of the pulmonary 
vasculature from well-characterized female PAH patients (PAH-
hPASMCs) and control subjects without PAH (control hPASMCs; 
provided by N. Morrell, University of Cambridge, Cambridge, 
United Kingdom). Patient details are shown in Table S1 in the online-
only Data Supplement. As comparator cells, in some experiments, 
we also studied human vascular SMCs (hVSMCs) from peripheral 
arteries obtained from gluteal biopsies of healthy women. Cells were 
used between passages 3 and 6 and processed as we described.20 
Experimental procedures using hPASMCs conform to the princi-
ples outlined in the Declaration of Helsinki and were approved by 
Cambridgeshire 1 Research Ethics Committee (REC reference: 08/
H0304/56).
Cell Protocols
Cells were stimulated with estrogen or 16αOHE1 (1 nmol/L; 5 
minutes to 48 hours). In some protocols, cells were pretreated (30 
minutes) with pharmacological inhibitors: 2-acetylphenothiazine 
(ML171; Nox1 inhibitor, 1 µmol/L), GKT137831 (Nox1/4 inhibitor, 
1 µmol/L), gp91ds-tat (Nox2 inhibitory peptide or scrambled con-
trol peptide, 10 µmol/L), 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-
(2-piperidinylethoxy) phenol]-1H-pyrazole dihydrochloride (MPP; 
ERα antagonist, 100 nmol/L), 4-[2-phenyl-5,7-bis(trifluoromethyl)
pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP; ERβ antagonist, 100 
nmol/L), 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (tempol; 
SOD mimetic, 10 µmol/L), and 2,3′,4,5′-tetramethoxystilbene (TMS; 
CYP1B1 inhibitor, 100 nmol/L). Doses were based on preliminary 
experiments and published data as detailed in the online-only Data 
Supplement.
Lucigenin-Enhanced Chemiluminescence
Lucigenin-enhanced chemiluminescence was used to determine ROS 
generation in cell lysates as we described.20,21
Amplex Red Assay
H2O2 was assessed in cell lysates with Amplex Red assay kit accord-
ing to manufacturer’s instructions.
Immunoblotting
Immunoblotting was used to examine protein expression of prolifer-
ating cell nuclear antigen, p27, Nox1 and Nox4, CYP1B1 and activa-
tion of signaling protein, p38mitogen-activated protein kinase, and 
irreversible oxidation of protein tyrosine phosphatases (PTPs).
PTP Oxidation
Irreversible oxidation of PTPs was assessed using an antibody (anti-
Ox-PTP) that specifically recognizes the sulfonic acid form of PTP 
cysteine residues as described.22
Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction was used to analyze 
mRNA expression. Total RNA was extracted, and real-time quantita-
tive polymerase chain reaction was carried out using SYBR Green I 
as described.23 Primers used were designed using the software Primer 
3 online (Table S2).
Nrf2 Activity Assay
Nrf2 activity was determined with the TransAM Nrf2 assay following 
manufacturer’s instructions.
5-Bromo-2′-Deoxyuridine Incorporation Assay
Cell proliferation was measured by 5-bromo-2′-deoxyuridine 
incorporation.
Hypoxic-Induced Pulmonary Hypertension in 
Female Nox1−/− and Nox4−/− Mice
All animal procedures conform to the UK Animal Procedures Act 
(1986), ARRIVE Guidelines,24 and the Guide for the Care and Use 
of Laboratory Animals (National Institutes of Health publication 
number, 85-23, revised 1996). Nox1−/− and Nox4−/− mice have pre-
viously been described.25,26 Mice were given free access to regular 
chow diet and water and were maintained on a 12-hour light/dark 
cycle. Development of hypoxic pulmonary hypertension in 18-week-
old female Nox1−/− and Nox4−/− mice and age-matched wild-type 
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(WT) female littermates (strain C57BL/6J) was achieved by 15 days 
exposure to hypobaric hypoxia (10% O2; 550 mbar) as described.27 
Mice maintained in normoxic conditions (21% O2; 1013 mbar) were 
studied as controls.
In Vivo Assessment of Pulmonary Hypertension
For all in vivo procedures, mice were assessed at 20 weeks of age 
and were anesthetized with inhaled isoflurane (3% in O2, induction; 
1.5% in O2, maintenance). In vivo pressure–volume loop relation 
measurements were performed to assess hemodynamic alterations in 
anesthetized mice 15 days after exposure to hypoxic conditions. A 
pressure–conductance catheter was inserted in the RV via the right 
jugular vein for right-heart catheterization and via the carotid artery 
for left ventricular catheterization (Millar Instruments, Houston, TX). 
After stabilization, steady-state measurements were recorded. RV 
systolic pressure (RVSP), RV end-systolic pressure, RV end-diastolic 
pressure, left ventricular systolic pressure, mean arterial pressure, 
heart rate, stroke volume, and cardiac output were determined.28–30 
RV hypertrophy (RVH) was assessed by bisecting the heart into the 
RV and left ventricle (LV) plus septum. RV and LV+septum ratio 
were determined (RV/[LV+septum]). Left ventricular hypertrophy 
was determined as left ventricular weight:tibia length.
Lung Immunohistochemistry to Assess Pulmonary 
Vascular Remodeling
Immediately after harvest, the left lung was perfusion fixed via the 
trachea. Lungs were processed into paraffin blocks for sectioning and 
stained for elastin and collagen using Van Gieson and Picrosirius red, 
respectively.27
Statistical Analysis
Mean value±SEM were calculated, and statistical comparisons were 
made with 1-way or 2-way ANOVA followed by Tukey post hoc test 
or 2-tailed Student t test where appropriate. P<0.05 was considered 
statistically significant.
Results
Estrogen and 16αOHE1 Increase ROS Production 
Through Nox
Basal ROS production was higher in PAH-hPASMCs com-
pared with control hPASMCs (Figure 1A). In control 
hPASMCs, estrogen induced a biphasic ROS response, with 
a rapid increase at 5 minutes and a second peak at 4 hours. 
In PAH-hPASMCs, estrogen induced a significant increase 
in ROS generation at 4 hours (Figure 1A). Estrogen-induced 
ROS production was blocked by ML171, a Nox1 inhibitor, 
and GKT137831, a dual Nox1/Nox4 inhibitor and the ROS 
scavenger, tempol (Figure 1B). The specific peptide inhibi-
tor of Nox2, gp91ds-tat, did not inhibit ROS production 
(Figure 1B).
Estrogen can be converted to 16αOHE1 by CYP1B1. 
2,3′,4,5′-tetramethoxystilbene, a selective CYP1B1 inhibitor, 
blocked estrogen- but not 16αOHE1-induced ROS produc-
tion in control hPASMCs and PAH-hPASMCs (Figure 1C; 
Figure S1). 16αOHE1 induced a rapid, but transient, increase 
in ROS generation in control hPASMCs, whereas in PAH-
hPASMCs, effects were sustained (Figure 1D). 16αOHE1-
stimulated ROS formation was inhibited by tempol (SOD 
mimetic), ML171, and GKT137831 (Figure 1E). No effects 
on ROS production were observed with the inhibitors alone 
(data not shown).
Basal H2O2 levels were reduced in PAH-hPASMCs ver-
sus control hPASMCs. 16αOHE1 decreased H2O2 production 
in control hPASMCs but markedly increased H2O2 levels 
in PAH-hPASMCs (Figure 2A). This may be via Nox1 and 
Nox4 as H2O2 production was inhibited by the Nox inhibitors, 
ML171 and GKT137831 (Figure 2A).
We next investigated the ER receptor subtype, mediat-
ing 16αOHE1 ROS effects. The ERα antagonist, 1,3-bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy) 
phenol]-1H-pyrazole dihydrochloride, but not the ERβ antag-
onist, 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]
pyrimidin-3-yl]phenol, inhibited 16αOHE1-induced ROS for-
mation in control and PAH-hPASMCs (Figure S2). No effects 
were observed with the ER antagonists alone (data not shown).
Regulation of Nox Isoforms and Nox Subunits by 
16αOHE1
Basal gene expression of Nox1 and Nox4 was increased in 
PAH-hPASMCs compared with control hPASMCs (Figure 2B 
and 2C). Nox2 transcript expression in both control hPASMCs 
and PAH-hPASMCs was below reliable levels of detection 
(data not shown). 16αOHE1 increased Nox1 expression in 
control hPASMCs to levels observed in PAH-hPASMCs 
(Figure 2B). In control hPASMCs, 16αOHE1 also increased 
gene expression of p47phox, the Nox subunit capable of acti-
vating Nox2 and Nox1 in the hybrid system in lieu of NoxO1, 
and poldip2, a Nox4 regulatory protein (Figure 2D). In PAH-
hPASMCs, 16αOHE1 increased transcript levels of NoxA1, 
NoxO1, and p47phox, subunits that regulate Nox1 (Figure 2E). 
Protein expression of Nox1 and Nox4 was increased in PAH-
hPASMCs compared with control hPASMCs, which is in 
agreement with transcript expression. Nox1, but not Nox4, 
protein levels were further increased after 16αOHE1 treat-
ment in PAH-hPASMCs (Figure S3).
Regulation of Nrf2 and Antioxidant Systems by 
16αOHE1
16αOHE1 had no significant effect on Nrf2 in control 
hPASMCs but reduced Nrf2 activity in PAH-hPASMCs. This 
effect seems to be dependent on conversion of estrogen to 
16αOHE1 as inhibition of CYP1B1, by 2,3′,4,5′-tetrame-
thoxystilbene, normalized Nrf2 activity in PAH-hPASMCs 
(Figure 3A). Expression of Bach1 (BTB and CNC homol-
ogy 1), a Nrf2 transcriptional repressor, was increased by 
16αOHE1 (Figure 3B) in control hPASMCs at 2, 8, and 48 
hours of stimulation. Basal levels of Nrf2-regulated anti-
oxidants, SOD1, catalase, and thioredoxin, were decreased 
in PAH-hPASMCs compared with control hPASMCs. 
16αOHE1 did not further modulate thioredoxin transcript 
levels. However, 16αOHE1 further reduced SOD1 in control 
hPASMCs where catalase was further reduced by 16αOHE1 
in PAH-hPASMCs (Figure 3C and 3E).
16αOHE1 Influences Redox Signaling
One of the most important consequences of oxidative stress 
is oxidation of proteins, particularly redox-sensitive PTPs, 
which regulate phosphorylation of downstream proteins, 
including mitogen-activated protein kinases, such as p38mi-
togen-activated protein kinase. 16αOHE1 significantly 
increased irreversible PTP oxidation in hPASMCs, an effect 
that was inhibited by GKT137831 (Figure 4A). 16αOHE1 
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induced a significant increase in phosphorylation of p38mito-
gen-activated protein kinase in hPASMCs, an effect that was 
attenuated in control hPASMCs pretreated with Nox1 inhibi-
tor, ML171 (Figure 4B).
16αOHE1-Induced Proliferation Involves Nox
16αOHE1 stimulated cell growth, as measured by 5-bromo-
2′-deoxyuridine incorporation in control hPASMCs and PAH-
hPASMCs (Figure 5A). These effects were attenuated by 
Figure 1. Estrogen (E2) and 16α-hydroxyestrone (16αOHE1) increase reactive oxygen species (ROS) production through nicotinamide 
adenine dinucleotide phosphate oxidase (Nox)-dependent mechanisms. Time-dependent increase of ROS production by E2 (1 nmol/L) in 
control human pulmonary artery smooth muscle cells (hPASMCs) and pulmonary arterial hypertension (PAH)-hPASMCs (A). A, hPASMCs 
and PAH-hPASMCs were exposed to E2 for the time of peak ROS production (4 h), in the presence or absence of inhibitors of Nox1 
(ML171, 1 µmol/L), Nox1/4 (GKT137831, 1 µmol/L), and Nox2 (gp91ds-tat or peptide control scrambled gp91ds-tat control peptide [Scr], 
10 µmol/L). B, Cells were also exposed to the superoxide dismutase mimetic tempol (10 µmol/L). C, E2-induced ROS production in the 
presence of cytochrome P450 1B1 inhibitor, 2,3′,4,5′-tetramethoxystilbene (TMS; 100 nmol/L). D, Time-dependent increase of ROS 
production by 16αOHE1. E, 16αOHE1-induced ROS production at peak time point, 30 minutes, in the presence or absence of tempol, 
ML171, GKT137831, or gp91ds-tat in control hPASMCs and PAH-hPASMCs. Data are expressed as relative light units (RLUs)/µg protein, 
expressed as percentage of vehicle (V) control conditions. Results are presented as mean±SEM of 6 to 7 experiments in triplicate. 
*P<0.05 and ***P<0.001 vs vehicle control hPASMCs; †P<0.05 and ††P<0.01 vs treated control hPASMCs; ‡P<0.05 and ‡‡‡P<0.001 vs 
vehicle PAH-hPASMCs; §P<0.05 and §§P<0.01 vs treated PAH-hPASMCs determined by ANOVA with Tukey post hoc test.
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GKT137831 and ML171 but not by gp91ds-tat. In addition, 
expression of DNA polymerase accessory factor and prolifer-
ation marker proliferating cell nuclear antigen was increased 
by 16αOHE1 at 2 hours (Figure 5B). Cyclin-dependent kinase 
inhibitor, p27, is able to bind to a broad spectrum of cyclin/
cyclin-dependent kinase complexes, inhibiting their activi-
ties, and as such can inhibit progression at every cell cycle 
phase. Therefore, decreased p27 levels have been associated 
with increased cell proliferation.31 Consistent with effects on 
proliferating cell nuclear antigen, 16αOHE1 decreased p27 
protein expression at 24 hours of stimulation (Figure 5C).
Effects of Estrogen and 16αOHE1 Are Specific  
to hPASMCs
To evaluate whether redox and proliferative effects of 
16αOHE1 are generalized phenomena or specific for 
hPASMCs, we also studied hVSMCs from peripheral arteries. 
16αOHE1 increased ∙O2− production in control hPASMCs but 
not in hVSMCs (Figure S4A). 16αOHE1 did not affect cell 
proliferation in hVSMCs (Figure S4B). Estrogen decreased 
ROS production in hVSMCs at 2 hours (Figure S5A). This 
had no effect on subsequent 5-bromo-2′-deoxyuridine incor-
poration in hVSMCs (Figure S5B).
Figure 2. Effect of 16α-hydroxyestrone (16αOHE1) on hydrogen peroxide (H2O2) production and nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase isoform expression. A, H2O2 production from cell lysates was measured by using Amplex Red assay in 
cells exposed to 16αOHE1 for 30 minutes in the presence or absence of ML171 and GKT137831. Data are expressed as relative light 
units (RLUs)/µg protein corrected to standard curve and expressed as percentage of vehicle (V) control conditions. Transcript levels of 
nicotinamide adenine dinucleotide phosphate oxidase (Nox)-1 (B) and Nox4 (C) and NADPH oxidase regulatory proteins in response 
to 16αOHE1 (4 h) in control human pulmonary artery smooth muscle cells (hPASMCs) (D) and pulmonary arterial hypertension (PAH)-
hPASMCs (E). Results are presented as mean±SEM of 6 experiments in triplicate. Graphs represent mRNA expression relative to GAPDH. 
*P<0.05, **P<0.01, and ***P<0.001 vs vehicle control hPASMCs; ‡P<0.05, ‡‡P<0.01, and ‡‡‡P<0.001 vs vehicle PAH-hPASMCs; 
§§P<0.01 vs 16αOHE1-treated PAH-hPASMCs, determined by ANOVA with Tukey post hoc test.
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Genetic Ablation of Nox1 and Nox4 Attenuates 
Development of Pulmonary Hypertension  
in Female Mice
To evaluate the pathophysiological significance of our in vitro 
findings, we extended our studies to an estrogen-dependent 
mouse model of pulmonary hypertension by examining female 
Nox1−/− and Nox4−/− mice exposed to hypoxic conditions. 
Under normoxic conditions, RVSP and RVH were not different 
between WT and Nox1−/− mice. Under hypoxic conditions, 
RVSP, RVH, RV end-diastolic pressure, and RV end-systolic 
pressure (Figure 6A through 6D) were increased in WT controls, 
responses that were attenuated in hypoxic Nox1−/− mice (Figure 
6). Similarly, vascular thickening (remodeling), as assessed by 
histological analysis, was increased in hypoxic compared with 
normoxic WT mice. No significant effects on vascular remod-
eling were observed in normoxic WT versus Nox1−/− mice. 
Figure 3. Effect of 16α-hydroxyestrone (16αOHE1) on nuclear factor E2–related factor 2 (Nrf2) activation and antioxidant gene expression. 
Nuclear translocation of Nrf2 by 16αOHE1 at 1 h was assessed as an indicator of Nrf2 activity, in the presence of cytochrome P450 1B1 
inhibitor, 2,3′,4,5′-tetramethoxystilbene (TMS). Data are expressed as relative light units (RLUs)/µg protein expressed as percentage of 
vehicle control conditions. A, Results are presented as mean±SEM of 6 experiments in triplicate. Effects of 16αOHE1 (2–48 h) on protein 
expression of Nrf2 transcriptional repressor, Bach1 (BTB and CNC homology 1). B, Protein expression is relative to β-actin. Antioxidant 
responses were assessed by investigating antioxidant gene expression downstream of Nrf2: superoxide dismutase-1 (SOD1) (C), catalase 
(D), and thioredoxin (TRDX) (E). Values are presented as mean±SEM of 6 experiments in triplicate and represent the mRNA expression 
relative to GAPDH. *P<0.05 vs vehicle control human pulmonary artery smooth muscle cells (hPASMCs); ‡P<0.05 vs vehicle (V) pulmonary 
arterial hypertension (PAH)-hPASMCs determined by ANOVA with Tukey post hoc test.
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However, under hypoxic conditions, Nox1−/− mice exhibited 
reduced vascular remodeling compared with hypoxic WT mice 
(Figure 6E). Cardiac output was decreased in hypoxic WT 
compared with normoxic WT mice (Figure S6A). Mean arterial 
pressure, stroke volume, left ventricular systolic pressure, left 
ventricular hypertrophy, and heart rate were unchanged across 
experimental groups (Figure S6B through S6F).
As shown in Figure 7A, in WT mice, hypoxia increased 
RVSP, and this was attenuated in hypoxic Nox4−/− mice (Figure 
7A). Hypoxic WT mice also showed increases in RVH, RV 
end-diastolic pressure, RV end-systolic pressure, pulmonary 
vascular remodeling (Figure 7B through 7E); with decreased 
cardiac output (Figure S7A), hallmarks of pulmonary hyper-
tension. However, these effects remained similar in Nox4−/− 
mice. No changes in mean arterial pressure, stroke volume, 
left ventricular systolic pressure, left ventricular hypertrophy, 
or heart rate were observed across the study groups (Figure 
S7B through S7F).
Expression of CYP1B1 in Female Mice With 
Pulmonary Hypertension
To evaluate indirectly whether estrogen metabolism in pul-
monary arteries may be altered in mice deficient in Nox, we 
assessed expression of CYP1B1, which catalyses estrogen to 
its metabolites, in pulmonary arteries of normoxic and hypoxic 
WT Nox1−/− and Nox4−/− mice. Expression of CYP1B1, at the 
protein and mRNA levels, was increased in hypoxic WT and 
Nox4−/− mice but not in hypoxic Nox1−/− mice (Figure S8).
Discussion
Major findings from our study show that in PASMCs from 
female subjects, the estrogen metabolite 16αOHE1 induces 
ROS production, downregulates the protective antioxidant 
effects of Nrf2, stimulates redox signaling, and promotes cell 
growth (Figure 8). Processes underlying these actions involve 
primarily Nox1 and ERα. 16αOHE1 effects are amplified in 
hPASMCs from female patients with PAH. In support of the 
Figure 4. 16α-hydroxyestrone (16αOHE1)–induced phosphorylation of p38MAPK and oxidation of protein tyrosine phosphatases (PTP). 
Irreversible oxidation of PTPs using the oxPTP antibody (A) and p38mitogen-activated protein kinase (p38MAPK) phosphorylation  
(B) were assessed after 16αOHE1 stimulation (1 h) in the presence or absence of ML171 and GKT137831. Results are representative of 
5 experiments where protein expression is relative to β-actin. **P<0.01 vs vehicle control human pulmonary artery smooth muscle cells 
(hPASMCs); †P<0.05 vs 16αOHE1-treated control hPASMCs, determined by ANOVA with Tukey post hoc test.
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importance of Nox1 in vascular processes associated with 
pulmonary hypertension, our in vivo studies showed that 
hypoxia-induced pulmonary hypertension and arterial remod-
eling were ameliorated in Nox1−/− mice but not in Nox4−/− 
mice. Nox1−/− mice also had reduced pulmonary artery 
content of the estrogen-metabolizing enzyme CYP1B1. Our 
study provides new molecular insights through Nox1/ROS 
and Nrf2 whereby 16αOHE1 influences hPASMC function, 
which when upregulated may contribute to vascular injury and 
remodeling in PAH, particularly important in women.
Studies have linked hormone replacement therapy and the 
contraceptive pill to the increased incidence of PAH32 giving 
rise to the hypothesis that estrogen and its metabolites play 
a role in the pathobiology of PAH. A metabolic shift toward 
the formation of proproliferative estrogen metabolites, includ-
ing 16αOHE1, by altered expression of CYP1B1, is associ-
ated with the development and progression of PAH.1 Although 
CYP1B1 expression is low under basal conditions, expression 
is upregulated in PAH. Relatedly, inhibition or loss-of-func-
tion of CYP1B1 is protective in preclinical PAH models, thus 
demonstrating that CYP1B1 is involved in the pathogenesis of 
PAH.1 In support of this, a CYP1B1 single nucleotide poly-
morphism has been associated with PAH and oncogenesis, 
and these pathways are thought to underpin sexual dimor-
phism in RV failure.12 In addition, 16αOHE1 upregulates 
MicroRNA-29, which alters molecular and functional indices 
of energy metabolism, contributing to PAH.33 Other pathways, 
involving ROS, have also been suggested in PAH and seem to 
be regulated by 16αOHE1 as we demonstrate here.
The ability of estrogen to induce ROS in hPASMCs was 
dependent on CYP1B1 activity and likely the production of 
estrogen metabolites because pharmacological inhibition of 
CYP1B1 prevented estrogen-induced, but not 16αOHE1-
induced, ROS production. Estrogens exert their cellular actions 
Figure 5. Role of nicotinamide adenine dinucleotide phosphate oxidase (Nox) in 16α-hydroxyestrone (16αOHE1)–mediated cell 
proliferation. To test if 16αOHE1 regulates proliferation in a Nox/reactive oxygen species–dependent manner, 5-bromo-2′-deoxyuridine 
(BrdU) incorporation was assessed in control human pulmonary artery smooth muscle cells (hPASMCs) and pulmonary arterial 
hypertension (PAH)-hPASMCs cultured for 24 h in the presence or absence of ML171, GKT137831, or gp91ds-tat (A). Results are 
representative of 6 experiments, in triplicate, where data are expressed relative to vehicle control conditions. Protein expression of 
cell growth marker proliferating cell nuclear antigen (PCNA) in response to 16αOHE1 (B) and cyclin-dependent kinase p27 (C) were 
determined by immunoblotting. Results are expressed as mean±SEM of 5 experiments where protein expression is relative to β-actin. 
*P<0.05 and **P<0.01 vs vehicle control hPASMCs; †P<0.05 and ††P<0.01 vs 16αOHE1-treated control hPASMCs; ‡P<0.05 vs vehicle 
PAH-hPASMCs; §P<0.05 vs 16αOHE1-treated PAH-hPASMCs determined by ANOVA with Tukey post hoc test.
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by activating their receptors, ERα, ERβ, and G-protein–coupled 
ER.34 In PAH, opposing roles of ERα and ERβ are described 
where increased pulmonary ERα expression has been associ-
ated with proliferation of PASMCs in human and experimental 
PAH.35,36 Inhibition of ERα reverses PAH in female mice but 
not in male hypoxic mice.35,36 Protective actions of estrogen on 
cell proliferation are mediated predominantly via ERβ signal-
ing.37 In our studies and in line with others, we observed that 
Figure 6. Effects of Nox1−/− on hypoxia-induced pulmonary hypertension in female mice. Pressure–volume loop was used to assess 
hemodynamic parameters to evaluate the development of pulmonary hypertension in Nox1−/− mice. Effects of Nox1−/− on right ventricular 
(RV) systolic pressure (RVSP) (A) and RV hypertrophy, calculated as RV weight/left ventricular+septum weight (B). RV end-diastolic 
pressure (RVEDP) (C), RV end-systolic pressure (RVESP) (D). Percentage of pulmonary vascular remodeling in distal pulmonary arteries 
in normoxic and hypoxic mice with representative images of pulmonary arteries (elastin Van Gieson stain; scale bar, 50 µm) (E). Data are 
presented as mean±SEM; n=8 to 10 per group. *P<0.05, **P<0.01, and ***P<0.001 vs wild-type (WT) normoxic; †P<0.05 and ††P<0.01 vs 
WT hypoxic, determined by 2-way ANOVA with Tukey post hoc test. ns indicates not significant.
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16αOHE1-induced ROS generation is mediated through ERα 
because 16αOHE1-mediated effects were blocked by 1,3-bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy) phenol]-
1H-pyrazole dihydrochloride (ERα antagonist) but not by 
4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimi-
din-3-yl]phenol (ERβ antagonist).
Hydroxyestrogens have also been shown to induce DNA 
damage either directly, through formation of DNA adducts, 
Figure 7. Effects of Nox4−/− on hypoxia-induced pulmonary hypertension in female mice. Pressure–volume loop was used to assess 
hemodynamic parameters to evaluate development of pulmonary hypertension female Nox4−/− mice. Effects of Nox4−/− on right ventricular 
(RV) systolic pressure (RVSP) (A) and RV hypertrophy, calculated as RV weight/left ventricular+septum weight (B). RV end-diastolic 
pressure (RVEDP) (C) and RV end-systolic pressure (RVESP) (D). Percentage of pulmonary vascular remodeling in distal pulmonary 
arteries in normoxic and hypoxic mice with representative images of pulmonary arteries (Elastin Van Giesen stain; scale bar, 50 µm) (E). 
Data are presented mean±SEM; n=8 to 10 per group. *P<0.05, **P<0.01, and ***P<0.001 vs wild-type (WT) normoxic; †P<0.05 vs WT 
hypoxic, determined by 2-way ANOVA with Tukey post hoc test. ns indicates not significant.
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or indirectly, through redox cycling and generation of ROS.38 
This further strengthens the concept that the deleterious actions 
of estrogen may be dependent on the conversion to 16αOHE1 
where results of our study implicated the generation of ROS as 
a mediator of these deleterious actions. Exact mechanisms of 
ROS production, especially with respect to estrogen/16αOHE1, 
are poorly understood. However, growing evidence implicates a 
role for Noxs, particularly Nox1 and Nox4, in the development 
and progression of PAH.39,40 We found increased basal levels 
of Nox1 and Nox4 in PAH-hPASMCs compared with con-
trol hPASMCs in agreement with other studies.18,40 16αOHE1 
induced an increase in expression of Nox1 and Nox subunits 
associated with Nox1 activation, whereas Nox4 and its regula-
tor poldip2 were not significantly modified in PAH-hPASMCs. 
These findings emphasize the preferential importance of Nox1 
versus Nox4 in PAH. Despite a role for Nox2 being reported 
by Liu et al,41 we were unable to delineate a role for Nox2 in 
our study. This may be related to the fact that Nox2 was almost 
undetectable in hPASMCs in our study.
Although Nox1 primarily produces ∙O2− and is reported to 
have deleterious effects in various components of the cardiovas-
cular system, a protective role of Nox4, which primarily produces 
H2O2, has been suggested.42 As such, Nox1 and Nox4 may exert 
opposing effects within the same tissue because of the difference 
in the reactive species produced. In our study, basal levels of 
H2O2 in PAH-hPASMCs were reduced, whereas 16αOHE1 was 
associated with excessive production of H2O2 in PAH-hPASMCs. 
It is well established that high concentrations of ROS can trig-
ger the oxidation of downstream signaling molecules, such as 
PTPs, resulting in the loss of function as a phosphate acceptor.43 
In association with excessive ROS production by 16αOHE1, we 
found an increase in irreversibly oxidized PTPs and enhanced 
phosphorylation of p38mitogen-activated protein kinase, which 
is downstream of PTP. Our findings support the notion that 
PTP inhibition is important in PAH, and we suggest that 
16αOHE1-induced ROS may be important in this process.
Our data indicate that in addition to regulating ROS produc-
tion, 16αOHE1 influences antioxidant systems in hPASMCs. 
In PAH-hPASMCs, 16αOHE1 increased ROS production 
and decreased Nrf2 activation, suggesting overall ROS accu-
mulation and oxidative stress. This effect was dependent on 
CYP1B1, suggesting a role for estrogen to 16αOHE1 conver-
sion in Nrf2 dysfunction in PAH-hPASMCs. Previous studies 
have reported Nox-derived ROS activating Nrf2 nuclear trans-
location in physiological states; however, in conditions of oxi-
dative stress and systemic vascular pathology, Nrf2 activation 
by Nox-derived ROS is dysregulated.19 Our data suggest that 
similar dysregulation of Nrf2 may occur in pathophysiologi-
cal conditions of the pulmonary vasculature.
In addition, we observed a decrease in the H2O2-reducing 
enzymes, catalase, and thioredoxin in PAH-hPASMCs com-
pared with control hPASMCs, where effects on catalase were 
further reduced in 16αOHE1-treated PAH-hPASMCs. This 
may be indicative of increased production and accumulation 
of H2O2 in PAH, potentiated by 16αOHE1. To better under-
stand the functional significance of 16αOHE1-induced oxi-
dative stress, we studied effects on proliferation, a hallmark 
of pulmonary vascular remodeling. 16αOHE1 stimulated 
ROS production in hPASMCs, expression of proliferating cell 
nuclear antigen and cell cycle inhibitors, and increased prolif-
eration, effects that were blocked by inhibitors of Nox1.
Taken together, our cell-based studies demonstrate that in 
hPASMCs, 16αOHE1 stimulates ROS production through ERα–
Nox–dependent processes. In PAH-increased Nox1 expression, 
oxidative stress and downregulation of the antioxidant Nrf2 
system lead to increased PTP oxidation, aberrant redox signal-
ing, and cell proliferation, as summarized in Figure 8. Because 
hPASMCs were derived from younger women than the patient 
cohort from whom we obtained PAH-hPASMCs cells, we can-
not exclude the possibility that aging or menopausal state may 
play a role. However, the differences observed in our study are 
likely independent of changes in ER status because vascular pro-
tein expression of ER does not change significantly with aging.44 
The cellular phenomena observed in our study seem to be 
specific for hPASMCs because hVSMCs from other vascular 
beds failed to respond to estrogen and 16αOHE1.
To further test the pathophysiological significance of our 
findings, we performed in vivo studies in Nox1−/− and Nox4−/− 
mice exposed to hypoxia. WT mice exhibited features of pul-
monary hypertension when exposed to hypoxic conditions as 
evidenced by increased RVSP, RV end-systolic pressure, RV 
end-diastolic pressure and RVH, processes that were attenu-
ated in Nox1−/− mice. Associated with pulmonary hypertensive 
changes, pulmonary arteries displayed significant remodeling, 
which was reduced in Nox1−/− mice but not in Nox4−/− mice. 
Figure 8. Schematic of putative role of 16α-hydroxyestrone 
(16αOHE1) in human pulmonary artery smooth muscle cells 
(PASMCs). The actions of 16αOHE1 and estrogen (E2) are 
mediated not only via the E2 receptors but also involve the 
activation of nicotinamide adenine dinucleotide phosphate 
oxidases (Noxs), which leads to ∙O2
− and hydrogen peroxide 
(H2O2) production. Excessive reactive oxygen species 
production coupled with impaired antioxidant mechanisms 
in response to 16αOHE1 may promote oxidation of protein 
tyrosine phosphatases (PTP) and enhanced signaling through 
p38mitogen-activated protein kinase (p38MAPK) and proteins 
involved in cell cycle regulation, leading to deleterious oxidative 
stress and pulmonary vascular proliferation. + indicates 
activation; and −, inhibition.
 at Glasgow University Library on July 12, 2016http://hyper.ahajournals.org/Downloaded from 
12  Hypertension  September 2016
A role for 16αOHE1 may be implicated here through the 
absence of hypoxia-induced increases in CYP1B1 expression 
in Nox1−/− mice. Only modest protective effects on RVSP were 
evident in hypoxic PH Nox4−/− mice; this is in alignment with 
a previous study using a small-molecule Nox4 inhibitor, show-
ing some effects on RVH and vascular remodeling.45 As such, 
the important role for Nox1 in mediating PAH phenotypes that 
were observed in vitro were paralleled in vivo where Nox1−/− 
mice were protected from hypoxia-induced vascular injury.
In conclusion, using hPASMCs from patients we show that 
the estrogen metabolite 16αOHE1 increases Nox-dependent 
ROS generation and decreases Nrf2–antioxidant systems that 
contribute to oxidative damage and redox-sensitive prolif-
eration of hPASMCs (represented schematically in Figure 8), 
processes critically involved in PAH. We identify Nox1 as 
being particularly important in hypoxia-induced pulmonary 
hypertension and in 16αOHE1-mediated vascular effects in 
PAH. Our study provides new molecular insights through 
Nox1/ROS and Nrf2 whereby 16αOHE1 influences pulmo-
nary artery VSMC function, which when upregulated may 
contribute to vascular injury and remodeling in PAH. Such 
phenomena may be especially important in female mice.
Perspectives
Metabolites of estrogen, including 16αOHE1, participate in many 
physiological processes implicated in cardiovascular complica-
tions associated with PAH. Current advances in the understanding 
of estrogen metabolism have provided insights into mechanisms 
involved in cardiopulmonary diseases. Our results identify Nox-
dependent redox signaling of 16αOHE1 as an important player in 
the molecular and cellular processes associated with PAH. Nox1 
is identified as a major player in 16αOHE1 effects.
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What Is New?
•	This study demonstrates that 16α-hydroxyestrone plays an important 
role in molecular and cellular processes associated with vascular injury 
and dysfunction through reactive oxygen species generation in pulmo-
nary hypertension.
What Is Relevant?
•	 Female mice develop pulmonary arterial hypertension more frequently 
than male mice. Estrogen metabolites, such as 16α-hydroxyestrone, 
and alterations in estrogen metabolism have also been implicated in the 
pathobiology of pulmonary arterial hypertension.
•	16α-hydroxyestrone stimulates nicotinamide adenine dinucleotide phos-
phate oxidase–derived reactive oxygen species generation, downregulates 
nuclear factor estrogen–related factor 2 and antioxidant systems, and induc-
es proliferation, effects that are specific to pulmonary artery smooth muscle 
cells. 16α-hydroxyestrone stimulates pulmonary artery smooth muscle cell 
reactive oxygen species production through estrogen receptor-α.
•	These data may contribute to a better understanding of cardiovascular 
complications in conditions associated with altered metabolism of estro-
gen, such as in pulmonary hypertension.
Summary
Increased levels of 16α-hydroxyestrone production have been 
implicated in pulmonary arterial hypertension, yet the underlying 
mechanisms remain elusive. Here, we describe a mechanism of 
action for 16α-hydroxyestrone and suggest that conversion of 
estrogen to 16α-hydroxyestrone leads to increased nicotinamide 
adenine dinucleotide phosphate oxidase-1– and nicotinamide ad-
enine dinucleotide phosphate oxidase-4–dependent reactive oxy-
gen species production, disrupted redox-sensitive protein tyrosine 
phosphatase and mitogen-activated protein kinase signaling, and 
decreased antioxidants, which contribute to oxidative damage and 
proliferation of pulmonary artery smooth muscle cells.
Novelty and Significance
 at Glasgow University Library on July 12, 2016http://hyper.ahajournals.org/Downloaded from 
MacLean and Rhian M. Touyz
Katie Y. Hood, Augusto C. Montezano, Adam P. Harvey, Margaret Nilsen, Margaret R.
Implications in Pulmonary Arterial Hypertension
-Hydroxyestrone in Human Pulmonary Artery Cells:αVascular Remodeling by 16
Mediated Redox Signaling and−Nicotinamide Adenine Dinucleotide Phosphate Oxidase
Print ISSN: 0194-911X. Online ISSN: 1524-4563 
Copyright © 2016 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Hypertension 
 published online July 11, 2016;Hypertension. 
Free via Open Access 
 http://hyper.ahajournals.org/content/early/2016/07/11/HYPERTENSIONAHA.116.07668
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://hyper.ahajournals.org/content/suppl/2016/07/11/HYPERTENSIONAHA.116.07668.DC1.html
Data Supplement (unedited) at:
  
 http://hyper.ahajournals.org//subscriptions/
is online at: Hypertension  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialHypertensionin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at Glasgow University Library on July 12, 2016http://hyper.ahajournals.org/Downloaded from 
1 
 
On-line Data Supplement  
 
Nox-mediated redox signaling and vascular remodeling by 16α-hydroxyestrone in 
human pulmonary artery cells: Implications in pulmonary arterial hypertension. 
 
Katie Y Hood BSc, Augusto C Montezano PhD, Adam P Harvey PhD, Margaret Nilsen, 
Margaret R MacLean* PhD, Rhian M Touyz* MD PhD. 
Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK. 
*Joint senior authors 
 
Short title: Estrogen, Nox and pulmonary hypertension. 
Address correspondence to: 
Rhian M. Touyz MD, PhD 
Institute of Cardiovascular and Medical Sciences,  
BHF Glasgow Cardiovascular Research Centre,  
126 University Place, University of Glasgow, G12 8TA, UK. 
Tel: +44(0)141 330 7775; Fax: +44(0)141 330 3360 
Email: rhian.touyz@glasgow.ac.uk  
 
 
  
2 
 
Detailed Methods 
Reagents 
The following antibodies were used: anti-Bach1 (Santa Cruz, sc-14700); anti-PCNA (Santa 
Cruz, sc-56); anti-p27(Santa Cruz, sc-1641); anti-Nox1 (Abcam, ab55831); anti-Nox4 (Abcam, 
ab133303); anti-CYP1B1 (Abcam, ab78044); anti-phospho-P38MAPK (Cell signalling, 
9211s); anti-Ox-PTP (R&D systems, MAB2844) and anti-β-actin (Abcam, ab8229).  
E2 (Cat.#2824) was purchased from Tocris, UK. 16αOHE1 (Cat.#E1250-000) was purchased 
from Steraloids, Newport, USA. MPP, an estrogen receptor alpha (ERα) antagonist 
(Cat.#M7068) 1 and PHTPP, an estrogen receptor beta (ERβ) antagonist (Cat.#SML1355) were 
purchased from Sigma, UK 1. GKT137831, a Nox1/4 inhibitor, was gifted by Genkyotex, 
Switzerland 2. ML171, a Nox1 inhibitor (Cat.#4653); SOD mimetic, tempol (Cat.#3082) 3 and 
Cytochrome P450 1B1 inhibitor, 2,3’,4,5’-Tetramethoxystilbene (TMS; Cat.#1509) 4 were 
purchased from Tocris, UK. Gp91ds-tat (Cat#AS-63818) 5, a peptide Nox2 inhibitor and 
scrambled control peptide were purchased from AnaSpec, USA.  
Cell culture 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Paisley, UK) 
supplemented with antibiotic antimycotic solution (containing 0.25µg/ml amphotericin B; 
100U/ml penicillin; 100µg/ml streptomycin; Sigma-Aldrich, Poole, UK) and 10% (v/v) fetal 
bovine serum (Sera Laboratories International, West Sussex, UK). Cells were grown to 70% 
confluence before serum deprivation for 24hours in charcoal-stripped 0.5% fetal bovine serum 
in phenol-red free DMEM prior to experiments to render them quiescent. Details of hPASMCs 
utilised can be found in Table S1. 
Lucigenin-enhanced chemiluminescence 
ROS generation was assessed in cell lysates by lucigenin-enhanced chemiluminescence assay 
as previously described3, 6. Control hPASMC, PAH-hPASMCs and hVSMCs were stimulated 
with E2 or 16αOHE1 for 5 minutes to 48 hours. In some experiments, cells were pre-exposed 
for 30 minutes to ML171, GKT137831, gp91ds-tat or scrambled peptide, tempol, MPP or 
PHTPP. Inhibitor studies were carried out at the peak time points for ROS production, 4hours 
stimulation for E2 and 30 minutes for 16αOHE1 treatment, respectively. Cells were washed 
with ice-cold PBS and harvested in lysis buffer (20mmol/L of KH2PO4, 1 mmol/L of EGTA, 
1μg/mL of aprotinin, 1μg/mL of leupeptin, 1μg/mL of pepstatin, and 1mmol/L of PMSF). 50µl 
of sample was added to a suspension containing 175μl of assay buffer (50mmol/L of KH2PO4, 
1mmol/L of EGTA, and 150mmol/L of sucrose) and lucigenin (5μmol/L). Luminescence was 
measured with a luminometer (AutoLumat LB 953, Berthold) before and after stimulation with 
NADPH (100µmol/l). A buffer blank was subtracted from each reading. Superoxide anion 
production was inhibited by tempol and was expressed as relative luminescence units 
(RLU)/µg protein, relative to vehicle control conditions.  
Amplex Red assay 
Hydrogen peroxide (H2O2) was assessed in cell lysates using the fluorescence assay Amplex 
Red Hydrogen Peroxide/Peroxidase Assay Kit (Life Technologies, Carlsbad, CA, USA) in 
accordance with manufacturer’s instructions and as we have previously described2. Briefly, 
Amplex Red (50 μmol/L) and horseradish peroxidase (0.1 U/mL) were added to the cellular 
samples. Fluorescence readings were made in a 96-well plate at Ex/Em = 530/590 nm using 50 
µl samples harvested in protein lysis buffer. H2O2 production was normalized to protein 
concentration. The results are expressed in arbitrary units per micro-gram protein, relative to 
vehicle control conditions. 
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Immunoblotting 
Proteins were extracted from cells and mouse pulmonary artery and immunoblotting was 
performed as we previously described7. All antibodies were used at 1:1000 dilution unless 
otherwise stated. After incubation with HRP-conjugated secondary antibodies, signals were 
revealed by chemiluminescence (WestPico, Pierce), visualized by autoradiography, and 
quantified densitometrically with open-source software ImageJ. Anti--actin antibody 
(1:10,000) was used as protein loading control. 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activity assay 
To assess nuclear accumulation of Nrf2, samples were prepared according to the 
manufacturer’s protocol using a nuclear extract kit (Active Motif, Carlsbad, CA). Nuclear 
preparations (10μg) were used for the TransAM Nrf2 ELISA kit (Active Motif, Carlsbad, CA) 
to measure DNA binding of activated Nrf2 nuclear protein, as determined by absorbance at 
450nm, following manufacturer’s instructions and as previously described.  
DNA synthesis by BrdU incorporation 
Cell proliferation by E2 and 16αOHE1 was measured by BrdU incorporation using a 
Proliferation Assay kit (Calbiochem, Darmstadt, Germany), according to the manufacturer’s 
instructions. Cells were seeded onto a 96-well plate and starved overnight before stimulation 
with E2 or 16αOHE1 in the absence or presence of ML171, GKT137831 or gp91ds-tat. Cells 
were incubated with BrdU for 24 hours. Absorbance was obtained at dual wavelength (450nm 
and 595nm) with a spectrophotometer (Spectra Max; Molecular Devices, Sunnyvale, CA, 
USA). The results were normalized as percent of control vehicle conditions. 
Hypoxia-induced pulmonary hypertension in Nox1-/- and Nox4-/- mice 
In studies involving the influence of the estrous cycle on non-reproductive functions, vaginal 
smear cytology is used to determine the cycle phases8. This was carried out prior to normoxic 
or hypoxic exposure to ensure this experimental model was commenced on the same cycle day 
for all mice. 
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Table S1. PAH Patient and non-PAH patient information. 
Patient Group Sex Age Disease Status 
Non-PAH Female 
 
57 COPD 
58 Mild emphysema  
59 Squamous cell carcinoma 
64 Mild emphysema 
64 Lung carcinoma 
70 Lobectomy 
71 Adenocarcinoma 
PAH Female 
 
24 IPAH 
30 HPAH (R899X) 
33 IPAH 
41 HPAH (N903S) 
53 IPAH 
39 IPAH 
 
Pulmonary artery smooth muscle cell subject origin and characteristics. Known characteristics 
of subjects from whom cells were derived. HPAH, heritable pulmonary arterial hypertension 
(gene mutation in parenthesis); IPAH idiopathic pulmonary arterial hypertension. 
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Table S2. Primers for qRT-PCR analysis. 
Gene Forward Primer Reverse Primer 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG 
Nox1 TCACCAATTCCCAGGATTGA TGTGGTCTGCACACTGGAAT 
Nox4 TGCAGCAAGATACCGAGATG GTGATCATGAGGAATAGCAC 
p47phox AGTCCTGACGAGACGGAAGA TACATGGACGGGAAGTAGCC 
p67phox AAGCTGTTTGCCTGTGAGGT CTGCTTCCAGACACACTCCA 
p40phox TCCTCCTCAGTCGGATCAAC TGATGGTGCTGATGGTGTCT 
NoxA1 CATGATGCCAGGTCCCTAAT CTCTGCTCCTGGTAGGCAGT 
NoxO1 GGTCCCCAGTTCTGTGCTT CGGTCTGACGTTTCCAACAC 
poldip2 AGTCTCTCTGGCACCTTGGA GAGAAGGGAGGAATCCGAAC 
p22phox AAGAGGAAGAAGGGCTCCAC GAGAGCAGGAGATGCAGGAC 
SOD1 GAAGGTGTGGGGAAGCATTA ACATTGCCCAAGTCTCCAAC 
Catalase CGTGCTGAATGAGGAACAGA AGTCAGGGTGGACCTCAGTG 
TRDX GCCTTTCTTTCATTCCCTCTC CCCACCTTTTGTCCCTTCTT 
CYP1B1 GCAGAAACTTCAACCCGATAA GAGCGGGGCGGAGAGT 
 
Primers targeted to the above genes were designed using Primer 3 software online, and were 
used to assess gene expression.  
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